Objectives
The overall goal of CATCH ALL is to integrate comprehensive information from adult and pediatric ALL patients to better understand the molecular and immunological mechanisms driving leukemia persistence and MRD for clinical translation. Building on our insights gained in the first funding period (2022-2026), the aim of the second funding phase is to further deepen our understanding of the molecular and immunological mechanisms driving leukemia persistence and MRD for clinical translation (2026-2030). We therefore propose the following specific scientific objectives, which are closely interconnected as shown in the figure below.
Aims
- Dissecting the molecular diversity across age groups (P1, P4)
- Understanding clonal evolution and cellular hierarchies in ALL (P3, P4)
- Contribution of the tumor microenvironment and cellular niches (P1, P2, P3, P4, P6, P8)
- Implementation of novel immunotherapies in preclinical models (P1, P3, P4, P5, P6, P7)
- Sustainable age overriding structures for translation of diagnostic and individualized treatment recommendation into clinical care (P1, P3, P4, INF, Z)
